Concise review: Mesenchymal stem cell treatment for ischemic kidney disease
Authors:
Open Access
- 14 June 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 31 (9) , 1731-1736
Abstract
Ischemic kidney diseases are common clinical entities that bear high mortality and morbidity and may lead to irreversible loss of kidney function. Their pathophysiology is multifaceted, involves complex hormonal‐immunological‐cellular interactions, and leads to damage in multiple cell types, which is often resistant to conventional therapy. Thus, novel strategies are needed to repair the renal parenchyma and preserve kidney function. Mesenchymal stem cells (MSC) confer renal protection through paracrine/endocrine effects and to some degree possibly by direct engraftment. Their anti‐inflammatory and immune‐modulatory properties target multiple cascades in the mechanisms of ischemic kidney disease. This review focuses on recent progress on the use of MSC to prevent kidney injury in ischemic kidney injury, with a focus on the chronic form. Stem Cells 2013;31:1731‐1736Keywords
This publication has 42 references indexed in Scilit:
- Rationale of Mesenchymal Stem Cell Therapy in Kidney InjuryAmerican Journal of Kidney Diseases, 2013
- Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in Rat sepsis syndrome induced by cecal puncture and ligationJournal of Translational Medicine, 2012
- In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemiaTransplant International, 2011
- Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injuryNephrology Dialysis Transplantation, 2011
- Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney modelRenal Failure, 2010
- Angiomyeloproliferative Lesions Following Autologous Stem Cell TherapyJournal of the American Society of Nephrology, 2010
- Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass EffectStem Cells and Development, 2009
- Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injuryKidney International, 2007
- Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2007
- Cortical Microvascular Remodeling in the Stenotic KidneyArteriosclerosis, Thrombosis, and Vascular Biology, 2004